Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study”

Amy Hughes, Jade Clarson, Tessa Gargett, Wenbo Yu, Michael P. Brown, Angel F. Lopez, Timothy P. Hughes, Agnes S M Yong

Research output: Contribution to journalEditorial

1 Citation (Scopus)
LanguageEnglish
Pages55-57
Number of pages3
JournalLeukemia Research
Volume55
DOIs
Publication statusPublished - 1 Apr 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{fe91d7e3e3e14056a2b8ec949208b452,
title = "Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study”",
author = "Amy Hughes and Jade Clarson and Tessa Gargett and Wenbo Yu and Brown, {Michael P.} and Lopez, {Angel F.} and Hughes, {Timothy P.} and Yong, {Agnes S M}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.leukres.2017.01.009",
language = "English",
volume = "55",
pages = "55--57",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies

T2 - Leukemia Research

AU - Hughes, Amy

AU - Clarson, Jade

AU - Gargett, Tessa

AU - Yu, Wenbo

AU - Brown, Michael P.

AU - Lopez, Angel F.

AU - Hughes, Timothy P.

AU - Yong, Agnes S M

PY - 2017/4/1

Y1 - 2017/4/1

UR - http://www.scopus.com/inward/record.url?scp=85010379903&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2017.01.009

DO - 10.1016/j.leukres.2017.01.009

M3 - Editorial

VL - 55

SP - 55

EP - 57

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -